Interventional Cardiology. Группа авторов

stimulated C‐reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003; 108:1930–2.

      186 186 Verma S, Wang CH, Li SH, et al. A self‐fulfilling prophecy: C‐reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002; 106:913–9.

      187 187 Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336:973–9.

      188 188 Haverkate F, Thompson SG, Pyke SD, et al. Production of C‐reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. The Lancet. 1997; 349:462–6.

      189 189 Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998; 98:839–44.

      190 190 Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long‐term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000; 343:1139–47.

      191 191 Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C‐reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994; 331:417–24.

      192 192 Ridker PM, Rifai N, Rose L, et al. Comparison of C‐reactive protein and low‐density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347:1557–65.

      193 193 Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of c‐reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001; 285:2481–2485.

      194 194 Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004; 351:2599–610.

      195 195 Burke AP, Tracy RP, Kolodgie F, et al. Elevated C‐reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002; 105:2019–2023.

      196 196 Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377:1119–1131.

      197 197 Everett BM, Donath MY, Pradhan AD, et al. Anti‐inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol. 2018; 71:2392–2401.

      198 198 Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin‐1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double‐blind, placebo‐controlled trial. The Lancet. 2017; 390:1833–1842.

      199 199 Tardif J‐C, Kouz S, Waters DD, et al. Efficacy and safety of low‐dose colchicine after myocardial infarction. N Engl J Med. 2019; 381:2497–2505.

      200 200 Ridker PM, Everett BM, Pradhan A, et al. Low‐dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019; 380:752–762.

      201 201 Davies MJ, Gordon JL, Gearing AJ, et al. The expression of the adhesion molecules ICAM‐1, VCAM‐1, PECAM, and E‐selectin in human atherosclerosis. The Journal of pathology. 1993; 171:223–9.

      202 202 Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin‐6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000; 101:1767–72.

      203 203 Peter K, Nawroth P, Conradt C, et al. Circulating vascular cell adhesion molecule‐1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule‐1, E‐selectin, P‐selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol. 1997; 17:505–12.

      204 204 Libby P, Aikawa M. New insights into plaque stabilisation by lipid lowering. Drugs. 1998; 56 Suppl 1:9–13; discussion 33.

      205 205 Urbich C, Dernbach E, Aicher A, et al. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation. 2002; 106:981–6.

      206 206 Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003; 108:1049–52.

      207 207 Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003; 348:1104–11.

      208 208 Semb AG, van Wissen S, Ueland T, et al. et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol. 2003; 41:275–9.

      209 209 Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin‐18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001; 104:1598–603.

      210 210 Bayes‐Genis A, Conover CA, Schwartz RS. The insulin‐like growth factor axis: A review of atherosclerosis and restenosis. Circ Res. 2000; 86:125–30.

      211 211 Bayes‐Genis A, Conover CA, Overgaard MT, et al. Pregnancy‐associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001; 345:1022–9.

      212 212 Sangiorgi G, Mauriello A, Bonanno E, et al. Pregnancy‐associated plasma protein‐a is markedly expressed by monocyte‐macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques: a link between inflammation and cerebrovascular events. J Am Coll Cardiol. 2006; 47:2201–11.

      213 213 Jaffer FA, Libby P, Weissleder R. Molecular and cellular imaging of atherosclerosis: emerging applications. J Am Coll Cardiol. 2006; 47:1328–38.

      214 214 Constantinides P. Cause of thrombosis in human atherosclerotic arteries. Am J Cardiol. 1990; 66:37g–40g.

      215 215 Fayad ZA, Fuster V. Clinical imaging of the high‐risk or vulnerable atherosclerotic plaque. Circ Res. 2001; 89:305–16.

      216 216 Stefanadis C, Toutouzas K, Tsiamis E, et al.Thermal heterogeneity in stable human coronary atherosclerotic plaques is underestimated in vivo: the “cooling effect” of blood flow. J Am Coll Cardiol. 2003; 41:403–8.

      217 217 Ruehm SG, Corot C, Vogt P, et al. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001; 103:415–22.

      218 218 Lederman RJ, Raylman RR, Fisher SJ, et al. Detection of atherosclerosis using a novel positron‐sensitive probe and 18‐fluorodeoxyglucose (FDG). Nuclear Medicine Communications. 2001; 22:747–53.

      219 219 Ciavolella M, Tavolaro R, Taurino M, et al. Immunoscintigraphy of atherosclerotic uncomplicated lesions in vivo with a monoclonal antibody against D‐dimers of insoluble fibrin. Atherosclerosis. 1999; 143:171–5.

      220 220 Schmitz SA, Coupland SE, Gust R, et al. Superparamagnetic iron oxide‐enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Investigative Radiology. 2000; 35:460–71.

      221 221 Schmitz SA, Taupitz M, Wagner S, et al. Iron‐oxide‐enhanced magnetic resonance imaging of atherosclerotic plaques: postmortem analysis of accuracy, inter‐observer agreement, and pitfalls. Investigative Radiology. 2002; 37:405–11.

      222 222 Yuan C, Kerwin WS. MRI of atherosclerosis. Journal of Magnetic Resonance Imaging: JMRI. 2004; 19:710–9.

      223 223 Yuan C, Kerwin WS, Ferguson MS, et al. Contrast‐enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. Journal of magnetic resonance imaging: JMRI. 2002; 15:62–7.

      224 224 Asakura T, Karino T. Flow patterns and spatial distribution of atherosclerotic lesions in human coronary arteries. Circ Res. 1990; 66:1045–66.

      225 225 Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999; 282:2035–42.

      226 226 Chatzizisis YS, Coskun AU, Jonas M, et al. Role of endothelial shear stress